Hormonal
Exercise-induced irisin promotes the browning of white adipose tissue and increases energy expenditure, offering a potential therapeutic mechanism for managing obesity and metabolic syndrome.
Exercise is beneficial for metabolic health, partly through mechanisms involving irisin and fat browning, but you cannot currently rely on blood tests for irisin to track progress or prescribe specific doses. Focus on consistent physical activity, particularly resistance training, which may influence irisin pathways, rather than seeking 'irisin-boosting' supplements which lack robust human validation.
Irisin, a thermogenic adipomyokine produced by FNDC5 cleavage is involved in the browning of adipose tissue... Irisin promotes 'browning' of mature white adipocytes in response to exercise... Brown and beige adipose tissues increase energy expenditure through the uncoupling of oxidative metabolism from ATP production.
Why this rating
Strong evidence in animal models, but inconsistent and contradictory results in human studies regarding circulating levels and effects.
Source
Irisin: A Hope in Understanding and Managing Obesity and Metabolic Syndrome
Lidia Iuliana Arhire et al. · Frontiers in Endocrinology · 2019
DOI 10.3389/fendo.2019.00524
More from this paper
- Irisin acts as an insulin-sensitizing hormone that facilitates glucose uptake in skeletal muscle and improves hepatic glucose metabolism, potentially reducing the risk of type 2 diabetes.Moderate
- Irisin has anti-inflammatory properties in adipose tissue, suppressing pro-inflammatory cytokines and promoting the switching of macrophages from a pro-inflammatory (M1) to an anti-inflammatory (M2) state.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →